Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient

In esophageal squamous cell carcinoma (ESCC), the acquisition of treatment resistance and tumor recurrence remain major clinical challenges. Carcinoma-associated fibroblasts (CAFs), key components of the tumor microenvironment, are known to influence ESCC progression and therapeutic response. However, many aspects of CAFs' roles in tumor malignancy remain unknown, presumably due to inter-patient variability in ESCC patients. Various human ESCC cell lines available for research are thought to partially mimic the nature of human carcinoma. They are also propagated in vitro for years and decades in a Petri dish, resulting in adaptation to the culture conditions. Moreover, human ESCC cell lines harbor various genetic and epigenetic alterations distinct among the original patients, resulting in inter-patient variability. Nevertheless, long-term cultured cancer cell lines have been employed in most previous studies for experimentation with patient-mismatched CAFs. Inter-patient variability within each cancer cell line and between cancer cells and CAFs might therefore cause reduced reproducibility and reliability of results. To eliminate inter-patient variability, three distinct cell types were isolated from the same patient: cancer organoids and CAFs from a surgically dissected ESCC region, and counterpart fibroblasts (CFs) from an adjacent non-tumorous region as patient-specific controls for CAFs. A detailed protocol is presented that enables the simultaneous isolation of cancer organoids, CAFs, and CFs. The cancer organoids grew well under three-dimensional conditions. CAFs and CFs stained positively for vimentin, one of the fibroblast markers, supporting the enrichment of these cells in fibroblastic lineages. The described protocol enables us to establish ESCC organoids and patient-matched fibroblasts, providing a valuable experimental platform that excludes inter-patient variability in studying tumor-stromal interactions.

Authors

Institutions

Publication Details

Journal
Journal of Visualized Experiments
Published
2026-04-03
DOI
https://doi.org/10.3791/69548
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient

Akira Orimo, Peining Zhang, Tadasuke Hashiguchi, Tetsu Fukunaga et al.
Journal of Visualized Experiments
Esophageal Cancer Research and Treatment
article

Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient

Akira Orimo, Peining Zhang, Tadasuke Hashiguchi, Tetsu Fukunaga, Hajime Orita, Motomi Nasu, Kazunari Yamashita, Tetsuo Kobayashi, Misaki Nomura, Takashi Hashimoto, Shinji Mine, Masaaki Abe
article en

Abstract

In esophageal squamous cell carcinoma (ESCC), the acquisition of treatment resistance and tumor recurrence remain major clinical challenges. Carcinoma-associated fibroblasts (CAFs), key components of the tumor microenvironment, are known to influence ESCC progression and therapeutic response. However, many aspects of CAFs' roles in tumor malignancy remain unknown, presumably due to inter-patient variability in ESCC patients. Various human ESCC cell lines available for research are thought to partially mimic the nature of human carcinoma. They are also propagated in vitro for years and decades in a Petri dish, resulting in adaptation to the culture conditions. Moreover, human ESCC cell lines harbor various genetic and epigenetic alterations distinct among the original patients, resulting in inter-patient variability. Nevertheless, long-term cultured cancer cell lines have been employed in most previous studies for experimentation with patient-mismatched CAFs. Inter-patient variability within each cancer cell line and between cancer cells and CAFs might therefore cause reduced reproducibility and reliability of results. To eliminate inter-patient variability, three distinct cell types were isolated from the same patient: cancer organoids and CAFs from a surgically dissected ESCC region, and counterpart fibroblasts (CFs) from an adjacent non-tumorous region as patient-specific controls for CAFs. A detailed protocol is presented that enables the simultaneous isolation of cancer organoids, CAFs, and CFs. The cancer organoids grew well under three-dimensional conditions. CAFs and CFs stained positively for vimentin, one of the fibroblast markers, supporting the enrichment of these cells in fibroblastic lineages. The described protocol enables us to establish ESCC organoids and patient-matched fibroblasts, providing a valuable experimental platform that excludes inter-patient variability in studying tumor-stromal interactions.

Journal of Visualized Experiments(230)
Juntendo University (JP)
Good health and well-being
Openalex Percentile: Top 29%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.